Earlier this month, I showed you just how oversold pharmaceutical makers and developers have become after presidential hopeful Hillary Clinton’s tweet about price gouging. I recommended Gilead as a great rebound play on this theme. Since then, it’s recovered as much as 8.3% of its share price. Today, we have a different development. Pfizer (NYSE: PFE) announced that it approached Allergan (NYSE: AGN), the maker of Botox, about a deal to combine forces. Allergan confirmed this news and told reporters that it is indeed a friendly negotiation and that it would create the largest pharmaceutical company in the world —… Read More
Earlier this month, I showed you just how oversold pharmaceutical makers and developers have become after presidential hopeful Hillary Clinton’s tweet about price gouging. I recommended Gilead as a great rebound play on this theme. Since then, it’s recovered as much as 8.3% of its share price. Today, we have a different development. Pfizer (NYSE: PFE) announced that it approached Allergan (NYSE: AGN), the maker of Botox, about a deal to combine forces. Allergan confirmed this news and told reporters that it is indeed a friendly negotiation and that it would create the largest pharmaceutical company in the world — topping even Johnson & Johnson (NYSE: JNJ).The combined company would be worth around $330 billion. That would make it the sixth largest company in the world, ahead of General Electric (NYSE: GE), J&J and Procter & Gamble (NYSE: PG). And it’s not because Pfizer thinks more people are going to heading into the Botox fad. Allergan is located in Ireland. In other words, U.S. politicians wouldn’t be able to touch the new company if it keeps its Dublin address. Although the merger was first proposed by Pfizer it will actually only benefit Allergan shareholders. You see, Allergan has serious baggage. Read More